Anesthetic Implications of Patients on Buprenorphine

Perioperative Management Strategies

• The Society for Perioperative Assessment and Quality Improvement (SPAQI) recommends individualizing perioperative buprenorphine management based on patient-specific factors, such as prescribed daily dose, indication for treatment, risk of relapse, and expected level of postsurgical pain 1, 2, 3
• The American College of Physicians and other medical societies suggest continuing buprenorphine therapy perioperatively, with consideration of tapering to 12 mg daily 2-3 days before surgery if high postoperative pain is anticipated, to minimize the risk of relapse and ensure adequate pain management 1, 4

Pain Management Considerations

• Patients on buprenorphine may require higher doses of full mu-opioid agonists to achieve adequate analgesia due to partial blockade of opioid receptors, and multimodal analgesia should be maximized, including regional anesthesia techniques, non-opioid adjuncts, and local anesthetic infiltration by the surgeon 1, 5
• The British Journal of Anaesthesia suggests that regional anesthesia techniques can be an effective way to manage pain in patients on buprenorphine, and should be considered when appropriate 5

Potential Complications and Monitoring

• The Mayo Clinic Proceedings recommends monitoring for potential drug-drug interactions that could result in QT-interval prolongation, serotonin syndrome, paralytic ileus, or precipitation of withdrawal symptoms, particularly when buprenorphine is combined with other CNS depressants 1
• Concomitant use of buprenorphine with QT-prolonging agents is contraindicated, and patients with certain medical conditions, such as adrenal insufficiency, increased intracranial pressure, or impaired consciousness, require special consideration 1, 5

Common Pitfalls and Caveats

• Abrupt discontinuation of buprenorphine in patients with opioid use disorder may precipitate withdrawal and increase risk of relapse, and coordination with the patient's buprenorphine provider is essential for perioperative planning and postoperative follow-up 5, 6

Buprenorphine for Severe Postoperative Pain Management in Patients on Chronic Buprenorphine Therapy

Preoperative Management

• The British Journal of Anaesthesia recommends continuing buprenorphine at the preoperative dose in almost all circumstances for patients already on chronic buprenorphine therapy 7, 8
• For patients on ≤12 mg sublingual daily, the British Journal of Anaesthesia suggests continuing the dose unchanged perioperatively 7, 8
• For patients on >12 mg sublingual daily, consideration should be given to tapering to 12 mg sublingual 2-3 days before surgery if high postoperative pain is anticipated 7

Intraoperative and Postoperative Pain Management

• The British Journal of Anaesthesia recommends implementing aggressive multimodal analgesia as the cornerstone of treatment, including regional anesthesia techniques and non-opioid adjuncts such as NSAIDs, acetaminophen, and ketamine 7, 8, 9
• Full mu-opioid agonists at higher-than-normal doses (expect 2-4 times typical requirements) may be necessary for breakthrough pain due to buprenorphine's partial agonist activity creating competitive receptor blockade 7
• Dividing the maintenance buprenorphine dose and administering every 6-8 hours rather than once daily can provide more consistent analgesia 7, 10

Monitoring and Management

• The World Journal of Emergency Surgery suggests monitoring respiratory status, sedation level, and pain scores regularly 9

Continuation of Buprenorphine (Suboxone) During the Peri‑operative Period

Primary Recommendation

• Maintain the patient’s baseline Suboxone (buprenorphine‑naloxone) dose unchanged throughout the peri‑operative period, even when prescribing hydrocodone/acetaminophen for postoperative pain. This recommendation is supported by expert consensus from the Perioperative Pain and Addiction Interdisciplinary Network (PAIN). [11][12]

Rationale for Continuation

Clinical Benefits

• Continuing buprenorphine almost always outweighs the risks of dose reduction or discontinuation; stopping it is rarely appropriate. (Expert consensus) [11][12]
• Abrupt cessation of buprenorphine precipitates opioid‑withdrawal symptoms and markedly raises the risk of relapse in individuals with opioid‑use disorder, leading to increased morbidity and mortality. (Expert consensus) 11
• Discontinuation undermines harm‑reduction strategies and reduces treatment retention for opioid‑use disorder, a condition with life‑threatening consequences. (Expert consensus) 11

Peri‑operative Analgesic Strategy

Foundation

• Continue the baseline Suboxone dose; consider dividing the daily dose into 6‑ to 8‑hour intervals to provide more consistent analgesic coverage. (Expert consensus) [11][12]

Adjunctive Non‑Opioid Measures

• Employ regional anesthesia techniques, peripheral nerve blocks, or local anesthetic infiltration whenever anatomically feasible to enhance pain control. (Expert consensus) [11][12]
• Add adjunct medications such as ketamine, gabapentin/pregabalin, or dexmedetomidine to further reduce the need for full‑mu opioid agonists. (Expert consensus) 11

Opioid Breakthrough Management

• Hydrocodone/acetaminophen (Vicodin) may be used on top of continued buprenorphine for breakthrough pain, recognizing that higher‑than‑usual opioid doses are often required because buprenorphine’s high receptor affinity limits displacement by full agonists. (Expert consensus) [11][12]

Practical Algorithm (Key Steps)

All bullet points are derived from cited sources (11, 12) and reflect the consensus‑based guidance of the Perioperative Pain and Addiction Interdisciplinary Network (PAIN).

Peri‑operative Pain Management for Patients on Low‑Dose Buprenorphine (≤12 mg/day)

Buprenorphine Continuation

• The Perioperative Pain and Addiction Interdisciplinary Network recommends that buprenorphine therapy be maintained throughout the peri‑operative period and that dose reduction is rarely appropriate, regardless of indication or formulation. 13
• The 2021 SPAQI consensus statement states that low‑dose buprenorphine formulations (< 12 mg/day) can be continued unchanged peri‑operatively; a 6 mg daily regimen falls well below the threshold where dose reduction would be considered. 13
• Splitting a 6 mg daily buprenorphine dose into either 2 mg every 8 hours or 3 mg every 12 hours provides more consistent analgesic coverage throughout the day. 14

Multimodal Non‑Opioid Analgesia

• Aggressive use of non‑opioid adjuncts (NSAIDs, acetaminophen, local anesthetic infiltration, and cryotherapy) should be the cornerstone of postoperative pain control for patients maintained on buprenorphine. 13
• Ice packs and limb/oral‑cavity elevation for the first 48 hours are recommended to reduce swelling and pain. 14

Breakthrough Opioid Analgesia

• Full mu‑opioid agonists (e.g., hydrocodone/acetaminophen or oxycodone) should be added on top of continued buprenorphine for breakthrough pain, recognizing that higher‑than‑usual doses are often required because buprenorphine’s high receptor affinity creates competitive blockade. 13
• Clinicians should anticipate prescribing 2–4 times the typical opioid dose to achieve adequate analgesia in this population. 13
• For complex oral surgery involving bone grafts, a regimen of oxycodone 10–15 mg every 4–6 hours as needed (instead of the usual 5–10 mg) is suggested. 13
• If pain remains uncontrolled after optimizing non‑opioid adjuncts, upward titration of the full agonist dose is advised. 13

Pre‑ and Post‑operative Implementation

• Pre‑operative verification of the patient’s current buprenorphine dose and the timing of the last dose should be performed. 14
• The surgical and anesthesia teams must be informed that buprenorphine will be continued unchanged throughout the peri‑operative period. 13
• On the day of surgery, the patient should take the scheduled morning buprenorphine dose as usual. 13
• Post‑operative days 1–5: continue the 6 mg daily buprenorphine (or the split‑dose regimen) together with scheduled NSAID and acetaminophen dosing, and provide breakthrough hydrocodone/acetaminophen 10/325 mg every 4–6 hours as needed. 13
• Post‑operative days 6–14: taper short‑acting opioid analgesics as pain improves while maintaining non‑opioid adjuncts; return to the baseline once‑daily buprenorphine schedule once split‑dosing is no longer needed. 13

Safety Monitoring

• Respiratory status should be closely monitored when high‑dose opioids are administered on top of buprenorphine, although buprenorphine’s ceiling effect offers some protection against respiratory depression. 14

Care Coordination

• The patient’s buprenorphine prescriber should be contacted before and after surgery to coordinate medication management and document any controlled‑substance prescriptions. 14